Definium Therapeutics to Highlight Phase 3 Data in Upcoming Investor Conferences
Event summary
- Definium Therapeutics (Nasdaq: DFTX) will present at three investor conferences in September 2026.
- Stifel-hosted webinar on September 1, 2026, to discuss Phase 3 Voyage study results for DT120 ODT in GAD.
- TD Cowen’s Neuropsychiatry Summit and Leerink Partners Biopharma Summit scheduled for September 23–25, 2026.
- Webcasts and replays available on Definium’s Investor Relations website for 90 days post-event.
The big picture
Definium Therapeutics is positioning itself as a leader in psychedelic-based treatments for psychiatric disorders, with a focus on translating clinical data into marketable therapeutics. The upcoming conferences are critical for validating its Phase 3 results and securing investor support amid a growing field of neuropsychiatry innovators. The success of DT120 ODT could set a precedent for future psychedelic-derived therapies.
What we're watching
- Clinical Validation
- How the Phase 3 Panorama topline results will impact DT120 ODT’s regulatory pathway.
- Market Positioning
- Whether Definium can differentiate itself in the competitive neuropsychiatry space.
- Investor Sentiment
- The pace at which investor confidence grows following these key data presentations.
Related topics